Northeastern University College of Science Dean Kenneth Henderson delivered the opening lecture at the Universities of Scotland Inorganic Chemistry Conference earlier this week, held at the University of Strathclyde in Glasgow, Scotland.
Professor John Engen helped develop a new hybrid technique to study how a critical HIV protein changes shape to allow infected cells to evade the immune system.
John de la Parra has a goal of using his love of plants to find new medicines from indigenous cultural practices and then bring in the full power of modern biotechnology to create a a controllable platform to create the medicines desperately needed for disease.
Derion Reid, Chemistry PhD candidate, sits down with the College of Science Graduate Program staff to talk about what it’s like to work and study at Northeastern University.
Boston is the apex of today’s biotechnology world. With over 250 companies in Boston, Cambridge, and surrounding suburbs, nearly every pharmaceutical company has a stake in Boston’s biotech network.
Alexander R. Ivanov’s paper, “Mass-Spectrometry-Based Molecular Characterization of Extracellular Vesicles: Lipidomics and Proteomics” was recognized by C&EN’s publication ‘Supplement” as one of the top ten chromatography and mass spectrometry papers.
A short course by Olga Vitek focused on how to keep up in the field of proteomics when the rapid advancements make it tough to interpret and translate meaningful results.
While on co-op at Woods Hole Oceanographic Institution in Cape Cod, Elliott Mueller is testing Martian meteorites and lunar samples from the Apollo missions.
In a paper published in Nature Chemistry, Northeastern University physics professor Paul Champion, uses ultrafast laser technology to determine how physics and chemistry combine to make biology happen.
Spencer Martin is working at Ernst & Young as part of the pharmaceuticals team, preparing for and performing mergers and acquisitions of Indian and multi-national pharmaceutical companies.